Suparna Clasen, MD
Cardiovascular Disease · Philadelphia, PANPI 1700171212
Payments from drug & device makers
What this record shows
Eli Lilly accounts for 81.3% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $1,162, 7.5 times the $154 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in PA, where the typical reported total is $1,447.
Across 27 payments — averaging $52.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- E.r. Squibb & Sons, L.L.C.$97
- Novartis$92
- Boston Scientific$42
- Johnson & Johnson$20
- Irhythm Technologies, Inc.$15
Across 1 payment — averaging $187.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$187
What the payments were for
- Travel & lodging$73652%
- Food & beverage$69248%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 21 | $1,162 |
| E.r. Squibb & Sons, L.L.C. | 1 | $97 |
| Novartis | 1 | $92 |
| Boston Scientific | 2 | $42 |
| Johnson & Johnson | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $15 |
How this compares
$1,428 in reported general payments places this provider in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $104,329 |
| EntrestoSacubitril/Valsartan | 64 | $82,644 |
| JardianceEmpagliflozin | 66 | $80,905 |
| WegovySemaglutide | 13 | $16,870 |
| FarxigaDapagliflozin Propanediol | 16 | $8,667 |
| XareltoRivaroxaban | 13 | $7,105 |
| Metoprolol Succinate | 130 | $1,958 |
| Ezetimibe | 12 | $1,155 |
| Carvedilol | 102 | $839 |
| Atorvastatin Calcium | 86 | $732 |
| Ranolazine ErRanolazine | 17 | $721 |
| Losartan Potassium | 69 | $596 |
| Torsemide | 33 | $524 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $432 |
| Chlorthalidone | 23 | $412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $92 | $82,64464 claims |
| Johnson & JohnsonXarelto | $20 | $7,10513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.